AGIO - AGIOS PHARMACEUTICALS, INC.

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 31.49

Open

$ 32.19

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 31.39 - $ 32.19

52 Week Range

$ 19.80 - $ 35.50

Volume

419,310

Average Volume

Market Cap

1.75B

Beta (5Y Monthly)

$ 0.92

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-15-2024	12-31-2023	10-K
2	11-02-2023	09-30-2023	10-Q
3	08-03-2023	06-30-2023	10-Q
4	05-04-2023	03-31-2023	10-Q
5	02-23-2023	12-31-2022	10-K
6	11-03-2022	09-30-2022	10-Q
7	08-04-2022	06-30-2022	10-Q
8	05-05-2022	03-31-2022	10-Q
9	02-24-2022	12-31-2021	10-K
10	11-03-2021	09-30-2021	10-Q
11	07-29-2021	06-30-2021	10-Q
12	04-29-2021	03-31-2021	10-Q
13	02-25-2021	12-31-2020	10-K
14	11-05-2020	09-30-2020	10-Q
15	07-30-2020	06-30-2020	10-Q
16	04-30-2020	03-31-2020	10-Q
17	02-19-2020	12-31-2019	10-K
18	10-31-2019	09-30-2019	10-Q
19	08-01-2019	06-30-2019	10-Q
20	05-02-2019	03-31-2019	10-Q
21	02-14-2019	12-31-2018	10-K
22	11-01-2018	09-30-2018	10-Q
23	08-02-2018	06-30-2018	10-Q
24	05-04-2018	03-31-2018	10-Q
25	02-14-2018	12-31-2017	10-K
26	11-01-2017	09-30-2017	10-Q
27	08-08-2017	06-30-2017	10-Q
28	05-04-2017	03-31-2017	10-Q
29	02-16-2017	12-31-2016	10-K
30	11-03-2016	09-30-2016	10-Q
31	08-08-2016	06-30-2016	10-Q
32	05-09-2016	03-31-2016	10-Q
33	02-26-2016	12-31-2015	10-K
34	11-06-2015	09-30-2015	10-Q
35	08-07-2015	06-30-2015	10-Q
36	05-11-2015	03-31-2015	10-Q
37	02-24-2015	12-31-2014	10-K
38	11-07-2014	09-30-2014	10-Q
39	08-07-2014	06-30-2014	10-Q
40	05-09-2014	03-31-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Cantor Fitzgerald Reiterates Overweight on...
04/09/2024 12:27:08

Cantor Fitzgerald analyst Eric Schmidt reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Overweight.

RBC Capital Maintains Outperform on Agios ...
02/16/2024 16:58:17

RBC Capital analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and lowers the price targe...

Agios Pharmaceuticals Q4 Sales $7.10M Miss...
02/15/2024 12:03:22

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly sales of $7.10 million which missed the analyst consensus estimate of $7...

Earnings Scheduled For February 15, 2024
02/15/2024 10:17:01

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on rev...

Earnings Preview: Agios Pharmaceuticals
02/14/2024 17:01:53

Agios Pharmaceuticals Announced Strong Cas...
01/08/2024 12:21:47

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases,...

why-is-blood-disorder-focused-agios-pharmaceuticals-stock-trading-higher-today

Why Is Blood Disorder Focused Agios Pharma...
01/03/2024 14:45:57

Agios Pharmaceuticals Inc (NASDAQ: AGIO) says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent ...

Market-Moving News for January 3rd
01/03/2024 13:36:09

AGIO: 22% | Agios Pharmaceuticals shares are trading higher after the company announced its Phase 3 ENERGIZE study of Mitapivat...

12-health-care-stocks-moving-in-wednesdays-pre-market-session

12 Health Care Stocks Moving In Wednesday'...
01/03/2024 13:05:55

Agios Announces Phase 3 ENERGIZE Study Of ...
01/03/2024 11:33:59

Agios Presented Results Saturday From Phas...
12/10/2023 12:36:51

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases,...

Agios Announces Clinical Proof-of-Concept ...
11/20/2023 12:04:30

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases,...

Goldman Sachs Maintains Neutral on Agios P...
11/03/2023 14:18:26

Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price targ...

Agios Pharmaceuticals To Present Broad Set...
11/02/2023 13:22:11

– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study i...

Agios Pharmaceuticals' Cash, Cash Equivale...
11/02/2023 11:10:11

Agios Pharmaceuticals Q3 EPS $(1.64) Beats...
11/02/2023 11:08:06

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.64) per share which beat the analyst consensus estimate of...

Earnings Scheduled For November 2, 2023
11/02/2023 08:56:34

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on...

JP Morgan Maintains Neutral on Agios Pharm...
08/07/2023 15:43:45

JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price target from...

Earnings Scheduled For August 3, 2023
08/03/2023 10:59:00

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on reven...

Agios Pharmaceuticals Has Announced Exclus...
08/03/2023 10:49:45